Document:

EXHIBIT 4.2

         

        STOCK OPTION

        ASSUMPTION, AMENDING AND CONFIRMATION AGREEMENT

        THIS AGREEMENT made as of the 21st day of August, 2008.

        BETWEEN:

        ONCOGENEX PHARMACEUTICALS, INC. (formerly known as SONUS PHARMACEUTICALS, INC.), a corporation existing under the laws of the State of Delaware

        (hereinafter referred to as "Sonus")

        AND:

        ONCOGENEX TECHNOLOGIES INC., a corporation existing under the federal laws of Canada

        (hereinafter referred to as "OncoGenex")

        WHEREAS:

        A.        OncoGenex has issued and outstanding options entitling directors, officers, employees and consultants of OncoGenex to purchase an aggregate of up to 1,489,047 Common shares ("OncoGenex Common Shares") in the capital of OncoGenex (collectively the "OncoGenex
        Options") pursuant to the OncoGenex Amended and Restated Stock Option Plan (the "OncoGenex Stock Option Plan");

        B.        Pursuant to the OncoGenex Stock Option Plan each of the existing OncoGenex Options is evidenced by an option agreement between OncoGenex and the applicable optionee (each an "Option Agreement");

        C.        Pursuant to an arrangement agreement (the "Arrangement Agreement") between Sonus and OncoGenex dated as of May 27, 2008, the parties agreed to seek approval from the court for a statutory plan of arrangement (as amended prior to the Effective Time, the "Plan of
        Arrangement") under section 192 of the Canadian Business Corporations Act pursuant to which Sonus would acquire all of the issued and outstanding shares and debentures in the capital of OncoGenex in exchange for shares of common stock in the capital of Sonus ("Sonus Common Shares");

        D.        Under the Plan of Arrangement, each OncoGenex Option will be exchanged for an option (an "Assumed Option") to purchase Sonus Common Shares, and no other consideration will be provided therefor; and

        E.        To give effect to the Assumed Options and enable the holders of OncoGenex Options ("Optionholders") to purchase Sonus Common Shares upon exercise of the Assumed Options Sonus has agreed to assume OncoGenex's obligations under the

         

        
            

            JDS\349901\STORM\7722

            
                

            

            -2-

             

            

             

            OncoGenex Stock Option Plan, as amended hereby, and to assume and exchange OncoGenex Options for Assumed Options on the basis set out in the Plan of Arrangement.

            NOW THEREFORE for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereto agree as follows:

            1.         Definitions. Each term denoted herein by initial capital letters and not otherwise defined herein shall have the meaning ascribed thereto in the Plan of Arrangement unless the context requires otherwise.

            2.         Assumption of Plan and Options. In order to implement the Plan of Arrangement and enable Optionholders to purchase Sonus Common Shares pursuant to the Assumed Options on the basis set out in the Plan of Arrangement, Sonus shall, with effect from the Effective Time, assume, observe, perform and
            discharge all covenants, terms, conditions and obligations contained in the OncoGenex Stock Option Plan and the OncoGenex Options required to be observed, performed and discharged by OncoGenex in the place and stead of OncoGenex on the terms and conditions specified herein.

            3.         Terms of Plan. For greater certainty, and in order to give effect to the Assumed Options, the covenants, terms, conditions and obligations which Sonus will observe, perform and discharge in respect of the OncoGenex Stock Option Plan shall, with effect from the Effective Time, be deemed to be
            those in the OncoGenex Stock Option Plan, subject to the amendments as follows:

            
                	
                            (a)

                        	
                            each and every reference to a "Common Share" thereunder shall be deemed to be a reference to a Sonus Common Share and any reference to "Common Shares" under the OncoGenex Stock Option Plan shall be deemed to be a reference to Sonus Common Shares;

                        

            

            
                	
                            (b)

                        	
                            each and every reference to OncoGenex or the Company thereunder shall be deemed to be a reference to Sonus;

                        

            

            
                	
                            (c)

                        	
                            each and every reference to "Series B2 Issue Date" thereunder shall be deemed to be a reference to the Effective Time;

                        

            

            
                	
                            (d)

                        	
                            sections 2.9, 2.12, 2.14, 2.16, 2.28, 2.30, 2.33, 6.1 and 7.5 shall be deemed to be deleted in their entirety;

                        

            

            
                	
                            (e)

                        	
                            section 2.15 shall be deemed to be deleted in its entirety and replaced with the following:

                        

            

            ""Joint Actor" means a person acting "jointly or in concert with" another person as that phrase is interpreted in Section 96 of the Securities Act."

            
                	
                            (f)

                        	
                            section 2.19 shall be deemed to be deleted in its entirety and replaced with the following:

                        

            

             

            
                

                JDS\349901\STORM\7722

                
                    

                

                -3-

                 

                

                 

                ""Option Agreement" means an agreement, in the form attached hereto as Schedule "A" or in such other form as may be approved by the Board, whereby the Company grants to an Optionee and Option."

                
                    	
                                (g)

                            	
                                section 2.32 shall be deemed to be deleted in its entirety and replaced with the following:

                            

                

                ""Shares" means the common shares in the capital of the Company as constituted at the Effective Time provided that, in the event of any adjustment pursuant to Section 5, "Shares" shall thereafter mean the shares or other property resulting from the events giving rise to the adjustment."

                
                    	
                                (h)

                            	
                                the following paragraph shall be deemed to be added immediately following section 2.37 and prior to section 3:

                            

                

                "In addition, in this Plan, the terms "Effective Time" and "Reverse Stock Split" shall have the meanings given thereto in the plan of arrangement between the Company and OncoGenex Technologies Inc. under section 192 of the Canada Business Corporations Act pursuant to which the Company acquired all of the issued and outstanding
                shares and debentures in the capital of OncoGenex Technologies Inc."

                
                    	
                                (i)

                            	
                                the reference in Exhibit I to Schedule A to the OncoGenex Stock Option Plan to the address and telephone and facsimile numbers for the Company shall be deemed to be:

                            

                

                1522 217th Place SE, Suite 100 Bothell, WA 98021

                Telephone: 425-487-9500

                Facsimile: 425-686-1600

                
                    	
                                (j)

                            	
                                section 3.2 shall be deemed to be deleted in its entirety and replaced with the following:

                            

                

                "The maximum number of Shares which may be issuable pursuant to options granted under the Plan shall be equal to 7,464,761 Shares adjusted to reflect the Reverse Stock Split, or such additional amount as may be approved from time to time by the Board."

                
                    	
                                (k)

                            	
                                the first paragraph of section 4.4(c) shall be deemed to be deleted in its entirety and replaced with the following:

                            

                

                "Early Retirement, Voluntary Resignation or Termination Other than For Cause

                If the Optionee or, in the case of an Option granted to an Optionee who falls under the definition of Service Provider set out in Subsection 2.29(b), the Optionee’s employer, ceases to be a director, officer, employee or Service Provider, as the case may be, of the Company or a subsidiary of the Company due to his or her retirement at the request of his or her employer
                earlier than the

                 

                
                    

                    JDS\349901\STORM\7722

                    
                        

                    

                    -4-

                     

                    

                     

                    normal retirement date under the Company’s or a subsidiary's retirement policy then in force, or due to his or her termination by the Company or a subsidiary other than for cause, or due to his or her voluntary resignation, the Option then held by the Optionee shall be exercisable to acquire Vested Unissued Option Shares as follows:

                    
                        	
                                     

                                	
                                    (i)

                                	
                                    subject to Subsection 4.4(c)(ii), in the case of an employee of the Company or of a subsidiary of the Company, until the Expiry Date or the date which is sixty (60) days after the Optionee ceases to be an employee of the Company or a subsidiary of the Company, whichever is sooner, after which the Option held by such Optionee shall be
                                    cancelled;

                                

                    

                    
                        	
                                     

                                	
                                    (ii)

                                	
                                    in the case of a director and/or officer who is also an employee of the Company or of a subsidiary of the Company, until the Expiry Date or the date which is one (1) year after the Optionee ceases to be an employee of the Company or a subsidiary of the Company, whichever is sooner, after which the Option held by such Optionee shall be
                                    cancelled;

                                

                    

                    
                        	
                                     

                                	
                                    (iii)

                                	
                                    in the case of a director and/or officer who is not also an employee of the Company or a subsidiary of the Company, or in the case of a Service Provider, until the Expiry Date of the Option."

                                

                    

                    
                        	
                                    (l)

                                	
                                    section 8.9 shall be deemed to be deleted in its entirety and replaced with the following:

                                

                    

                    "No Optionee may assign any of his or her rights under the Plan without the consent of the Board."

                    4.         Terms of Assumed Options. For greater certainty, and in order to give effect to the Assumed Options, the covenants, terms, conditions and obligations which Sonus will observe, perform and discharge in respect of each OncoGenex Option and the Option Agreement evidencing the same shall,
                    pursuant to the Plan of Arrangement and with effect from the Effective Time, be deemed to be those in the respective Option and Option Agreement evidencing the same, subject to the amendments as follows:

                    
                        	
                                    (a)

                                	
                                    each and every reference to a common share therein shall be deemed to be a reference to a Sonus Common Share;

                                

                    

                    
                        	
                                    (b)

                                	
                                    each and every reference to OncoGenex or the "Company" therein shall be deemed to be a reference to Sonus;

                                

                    

                    
                        	
                                    (c)

                                	
                                    each and every reference to "Option Shares" therein shall be deemed to be a reference to that number of Sonus Common Shares as is equal to the product of the Share Exchange Ratio adjusted to reflect the Reverse Stock Split multiplied by the number of OncoGenex Common Shares subject to such Option Agreement (rounded down to the next whole
                                    number);

                                

                    

                     

                    
                        

                        JDS\349901\STORM\7722

                        
                            

                        

                        -5-

                         

                        

                         

                        
                            	
                                        (d)

                                    	
                                        each and every reference to "Option Price" therein shall be deemed to be the amount, expressed in U.S. dollars, obtained by (i) dividing the exercise price per share of the OncoGenex Option evidenced by such Option Agreement immediately prior to the Effective Time by (ii) the Share Exchange Ratio adjusted to reflect the Reverse Stock
                                        Split and (iii) multiplying the resulting quotient by the noon buying rate of exchange for one U.S. dollar in Canadian dollars as published by the Federal Reserve Bank of New York on the date immediately prior to the Effective Date or, if no rate was published on such date, the noon buying rate most recently published by the Federal Reserve Bank of New York preceding such date (rounded up to the nearest one hundredth of a cent);

                                    

                        

                        
                            	
                                        (e)

                                    	
                                        to the extent that OncoGenex Options have not been exercised prior to the Effective Time, each and every reference to a number of shares becoming Vested on a specific date under an Option Agreement shall be deemed to be a reference to that number of Sonus Common Shares as is equal to the product of the Share Exchange Ratio adjusted to
                                        reflect the Reverse Stock Split multiplied by the number of OncoGenex Common Shares referred to in the Option Agreement as becoming Vested on such dates (rounded to the next whole number provided such rounding does not reduce the aggregate number of Option Shares);

                                    

                        

                        
                            	
                                        (f)

                                    	
                                        for purposes of the foregoing, the terms “Effective Time”, “Reverse Stock Split” and “Share Exchange Ratio” shall have the meanings set forth in the Plan of Arrangement; and

                                    

                        

                        
                            	
                                        (g)

                                    	
                                        notwithstanding the above, in the event a holder of an OncoGenex Option would be subject to Section 409A of the Code as a result of the application of the terms of this agreement, the determination of Option Price and Option Shares with respect to such Optionee shall be adjusted as necessary such that the transactions contemplated herein
                                        satisfy the requirements of Treasury Regulation Section 1.409A-1(b)(5)(v)(D).

                                    

                        

                        5.         Other Terms. Other than as provided herein, the term to expiry, conditions to and manner of exercise and other terms and conditions of the Assumed Options shall be the same as the terms and conditions of the OncoGenex Options for which they are assumed and exchanged.

                        6.         Option Certificates or Notices. With effect from the Effective Time, any Option Agreement evidencing an OncoGenex Option shall be deemed to evidence an Assumed Option.

                        7.         Deemed Cancellation of OncoGenex Options. Upon the exchange of each OncoGenex Option for an Assumed Option to purchase Sonus Common Shares pursuant to the Plan of Arrangement, each such OncoGenex Option exchanged thereby shall be deemed to be terminated, and of no further force or
                        effect, and only the Assumed Option to purchase Sonus Common shares shall be deemed to exist in substitution thereof.

                         

                        
                            

                            JDS\349901\STORM\7722

                            
                                

                            

                            -6-

                             

                            

                             

                            8.         Notification of this Agreement and the Arrangement. Sonus shall, as promptly as practicable after the Effective Date, deliver to each of the Optionholders by pre-paid ordinary mail a notice of the terms of this Agreement and a confirmation of the number of Sonus Common Shares and
                            the relevant exercise price thereof under each of their respective Assumed Options.

                            9.         Notices. All notices and other communications which may or are required to be given pursuant to any provisions of this Agreement shall be given or made in writing and shall be deemed to be validly given if served personally or by telecopy, in each case addressed to the particular
                            party at:

                            
                                	
                                             

                                        	
                                            (a)

                                        	
                                            If to Sonus:

                                        

                            

                            Sonus Pharmaceuticals, Inc.

                            1522 217th Place SE

                            Suite 100

                            Bothell, WA 98021

                            
                                	
                                             

                                        	
                                            Attention:

                                        	
                                            Chief Executive Officer

                                        

                            

                            
                                	
                                             

                                        	
                                            Facsimile:

                                        	
                                            425-686-1600

                                        

                            

                            
                                	
                                             

                                        	
                                            (b)

                                        	
                                            If to OncoGenex:

                                        

                            

                            OncoGenex Technologies Inc.

                            400 – 1001 West Broadway

                            Vancouver, BC V6H 4B1

                            
                                	
                                             

                                        	
                                            Attention:

                                        	
                                            President and Chief Executive Officer

                                        

                            

                            
                                	
                                             

                                        	
                                            Facsimile:

                                        	
                                            (604) 736-3687

                                        

                            

                            or at such other address of which any party may, from time to time, advise the other parties by notice in writing given in accordance with the foregoing. The date of receipt of any such notice shall be deemed to be the date of delivery or telecopying thereof.

                            10.       Further Assurances. Each party hereto shall, from time to time, and at all times hereafter, at the request of the other party hereto, but without further consideration, do all such further acts and things and execute and delivery all such further documents and instruments as shall be
                            reasonably required in order to fully perform and carry out the terms and intent hereof.

                            11.       Governing Laws. This Agreement shall be governed by and construed in accordance with the laws of the Province of British Columbia and the laws of Canada applicable therein and shall be treated in all respects as a British Columbia contract.

                            12.       Binding Effect. This Agreement shall be binding upon and shall enure to the benefit of the parties hereto and their respective successors.

                             

                            
                                

                                JDS\349901\STORM\7722

                                
                                    

                                

                                -7-

                                 

                                

                                 

                                13.       Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument.

                                IN WITNESS WHEREOF the parties hereto have executed this Agreement as of the date first written above.

                                 

                                ONCOGENEX PHARMACEUTICALS, INC.

                                 

                                
                                    	
                                                Per:  /s/ Scott Cormack                        

                                            

                                

                                
                                    	
                                                 

                                            	
                                                Authorized Signatory

                                            

                                

                                ONCOGENEX TECHNOLOGIES INC.

                                 

                                
                                     

                                    
                                        	
                                                    Per:  /s/ Stephen Anderson                

                                                

                                    

                                

                                
                                    	
                                                 

                                            	
                                                Authorized Signatory

                                            

                                

                                 

                                 

                                
                                    

                                    JDS\349901\STORM\7722ex41to8k06113_08252008.htm

    Exhibit
4.1

    AMENDMENT
TO RIGHTS AGREEMENT

    

    THIS AMENDMENT TO RIGHTS AGREEMENT
(this “Amendment”) is made as of August 25, 2008 by New Century Equity
Holdings Corp., a Delaware corporation, (the “Company”), and The Bank of New
York Mellon Trust Company, N.A. (the “Rights Agent”):

    

    WHEREAS, the Company and the
Rights Agent are parties to a Rights Agreement dated as of July 10, 2006 (the
“Rights Agreement”);

    

    WHEREAS, the Company and
Dieter Esch (“Esch”), Lorex Investments AG (“Lorex”), Brad Krassner (“Krassner”)
and the Krassner Family Investments, L.P. (the “Krassner L.P.”) (each of Esch,
Lorex, Krassner and the Krassner L.P., a “Wilhelmina Seller and, collectively,
the “Wilhelmina Sellers”), Wilhelmina International, Ltd. (“Wilhelmina
International”) and certain entities affiliated with Wilhelmina
International  intend to enter into that certain agreement (the
“Wilhelmina Agreement”), pursuant to which, among other things, the Company will
issue Common Shares to the Selling Shareholders as partial consideration for the
acquisition of certain equity interests in Wilhelmina International and certain
entities affiliated with Wilhelmina International;

    

    WHEREAS, the Company desires
to amend the Rights Agreement so that the Wilhelmina Agreement and any
subsequent acquisition of Common Shares by Selling Shareholders pursuant to the
Wilhelmina Agreement does not affect any rights under the Rights Agreement;
and

    

    WHEREAS, pursuant to Section
27 of the Rights Agreement, the Board of Directors of the Company has determined
that an amendment to the Rights Agreement as set forth herein is necessary and
desirable in connection with the foreging and the Company and the Rights Agent
desire to evidence such amendment in writing.

    

    NOW, THEREFORE, BE IT RESOLVED
that the parties hereto hereby amend the Rights Agreement to the extent
and as provided as follows:

    

    1.  Amendment
of Section 1(a).  Section 1(a) of the Rights Agreement is amended to
add the following sentence at the end thereof:

    

    “Notwithstanding anything in this
Rights Agreement to the contrary, no Wilhelmina Seller nor any of their existing
or future Affiliates or Associates shall be deemed to be an Acquiring Person
solely by virtue of (i) the execution of the Wilhelmina
Agreement,  (ii) the acquisition of Common Shares pursuant to the
Wilhelmina Agreement, (iii) the consummation of any other transactions
contemplated by the Wilhelmina Agreement, or (iv) the issuance of stock options
to such Wilhelmina Seller or the exercise thereof.”

    

    2.  Amendment
of Section 1(ee).  Section 1(ee) of the Rights Agreement is amended to
add the following sentence at the end thereof:

    

     “;
provided,  however,  that no Triggering Event shall result
solely by virtue of (i) the  execution  of the Wilhelmina
Agreement,  (ii) the acquisition of Common Shares pursuant to the
Wilhelmina Agreement, (iii) the consummation of any other transactions
contemplated by the Wilhelmina Agreement, or (iv) the issuance of stock options
to any Wilhelmina Seller or the exercise thereof by such Wilhelmina
Seller.”

    

    3.  Amendment
of Section 1.  Section 1 of the Rights Agreement is amended to add a
new definition as subsection (ff) at the end thereof:

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    

    “(ff)  “Wilhelmina
Agreement” means that certain agreement dated August 25, 2008 by and among the
Company, Dieter Esch, Lorex Investments AG, Brad Krassner, the Krassner Family
Investments, L.P., Wilhelmina International, Ltd., certain entities affiliated
with Wilhelmina International, certain other individuals set forth on a schedule
thereto.

    

    4.   Amendment
of Section 1.  Section 1 of the Rights Agreement is amended to add a
new definition as subsection (gg) at the end thereof:

    

    “(gg)  “Wilhelmina
Seller” means Dieter Esch, Lorex Investments AG, Brad Krassner, Krassner Family
Investments, L.P., Sean Patterson, Kevin Garnett, Glenn Damota, Serge
Massat, Robert Kreusler, Eve Gianni, Marlene Wallach and Corey
Preston.

    

    5.  Amendment
of Section 3(a).  Section 3(a) of the Rights Agreement is amended to
add the following sentence at the end thereof:

    

    “Notwithstanding
anything in this Rights Agreement to the contrary, a Distribution Date shall not
be deemed to have occurred solely by virtue of (i) the execution of the
Wilhelmina Agreement, (ii) the acquisition of Common Shares pursuant to the
Wilhelmina Agreement, (iii) the consummation of any other transactions
contemplated by the Wilhelmina Agreement, or (iv) the issuance of stock options
to any Wilhelmina Seller or the exercise thereof by such Wilhelmina
Seller.”

    

    6.  Amendment
of Section 7(a).  Section 7(a) of the Rights Agreement is amended to
add the following sentence at the end thereof:

    

    “Notwithstanding anything in this
Rights Agreement to the contrary, neither (i) the execution of the Wilhelmina
Agreement;  (ii) the acquisition of Common Shares pursuant to the
Wilhelmina Agreement; (iii) the consummation of any other transactions
contemplated by the Wilhelmina Agreement; nor (iv) the issuance of stock options
to any Wilhelmina Seller or the exercise thereof by such Wilhelmina Seller,
shall be deemed to be events that cause the Rights to become exercisable
pursuant to the provisions of this Section 7 or otherwise.”

    

    7.  Amendment
of Section 11.  Section 11 of the Rights Agreement is amended to add
the following sentence after the first sentence of said Section:

    

    “Notwithstanding anything in this
Rights Agreement to the contrary, neither (i) the execution of the Wilhelmina
Agreement; (ii) the acquisition of Common Shares pursuant to the Wilhelmina
Agreement; (iii) the consummation of any other transactions contemplated by the
Wilhelmina Agreement; nor (iv) the issuance of stock options to any Wilhelmina
Seller or the exercise thereof by such Wilhelmina Seller, shall be deemed to
cause the Rights to be adjusted or to become exercisable in accordance with this
Section 11.”

    

    8.  Amendment of Section
13.  Section 13 of the Rights Agreement is amended to add the
following sentence at the end thereof:

    

    “Notwithstanding anything in this
Rights Agreement to the contrary, neither  (i) the execution of the
Wilhelmina Agreement; (ii) the acquisition of Common Shares pursuant to the
Wilhelmina Agreement; (iii) the consummation of any other transactions
contemplated by the Wilhelmina Agreement; nor (iv) the issuance of stock options
to any Wilhelmina Seller or the exercise thereof by such Wilhelmina Seller,
shall be deemed to be events of the type described in this Section 13 or to
cause the Rights to be adjusted or to become exercisable in accordance with
Section 13.”

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    

    9.  Amendment
of Section 25(a).  Section 25(a) of the Rights Agreement is amended to
add the following sentence at the end thereof:

    

    “Notwithstanding anything in this
Rights Agreement to the contrary, neither (i) the execution of the Wilhelmina
Agreement; (ii) the acquisition of Common Shares pursuant to the Wilhelmina
Agreement; (iii) the consummation of any other transactions contemplated by the
Wilhelmina Agreement; nor (iv) the issuance of stock options to any Wilhelmina
Seller or the exercise thereof by such Wilhelmina Seller, shall be deemed to
require the Company to provide notice in accordance with this Section
25.”

    

    10.  Effectiveness.
This Amendment shall be deemed effective as of the date first written above, as
if executed on such date. Except as amended hereby, the Rights Agreement shall
remain in full force and effect and shall be otherwise unaffected
hereby.

    

    11.  Miscellaneous.  This
Amendment shall be deemed to be a contract made under the laws of the
Commonwealth of Delaware and for all purposes shall be governed by and construed
in accordance with the laws of such state applicable to contracts to be made and
performed entirely within such state.  This Amendment may be executed
in any number of counterparts, each of such counterparts shall for all purposes
be deemed to be an original, and all such counterparts shall together constitute
but one and the same instrument.  If any provision, covenant or
restriction of this Amendment is held by a court of competent jurisdiction or
other authority to be invalid, illegal or unenforceable, the remainder of the
terms, provisions, covenants and restrictions of this Amendment shall remain in
full force and effect and shall in no way be effected, impaired or
invalidated.

    

    IN
WITNESS WHEREOF, this Amendment is effective as of the day and year first
referenced above.

    

    
      	 
      	
              NEW
      CENTURY EQUITY HOLDINGS CORP.

            
	 
      	 
      
	 
      	
              By:

            	
              
                /s/
      Mark Schwarz

              

            
	 
      	 
      	
              Name:

            	
              Mark
      Schwarz

            
	 
      	 
      	
              Title:

            	
              Acting
      Chief Executive Officer

            

    

    

    
      	 
      	
              THE
      BANK OF NEW YORK MELLON TRUST COMPANY, N.A.

            
	 
      	 
      
	 
      	
              By:

            	
              
                /s/
      Mauri J. Cowen

              

            
	 
      	 
      	
              Name:

            	
              Mauri
      J. Cowen

            
	 
      	 
      	
              Title:

            	
              Vice
      President

            

    

    

    

    CERTIFICATION
TO RIGHTS AGENT: The officer of the Company whose duly authorized signature
appears above certifies that this Amendment is in compliance with the terms of
Section 27 of the Rights Agreement.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00146-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00146-of-00352.parquet"}]]